Readers of Pharmaceutical Technology have been voting for which party’s victory in the...
- Conservative victory in general election best for UK pharma, Pharma Tech survey finds
- ViiV submits NDA for drug indicated for multi-drug resistant HIV
- Big pharma agrees to drastically cut prices of blockbuster drugs in China
- NICE recommends Pfizer’s Ibrance for NHS use through the CDF
- UK general election 2019: what are the parties’ promises to pharma?
Butterworth’s Statement on Brexit
Butterworth Laboratories Ltd, a UK-based a contract analytical chemistry testing laboratory working principally in the pharmaceutical market, has been continuously monitoring Brexit and its potential outcome over the last 12 months.
Conservative victory in general election best for UK pharma, Pharma Tech survey finds
Readers of Pharmaceutical Technology have been voting for which party’s victory in the UK’s upcoming general election will be best for the pharma industry. Although the Conservative Party is in the lead in the survey with 28%, it is only 5% above Labour, which is much closer than its ten-point lead in the national polls.
Amgen secures FDA approval for biosimilar drug Avsola
Amgen has received approval from the US Food and Drug Administration (FDA) for Avsola (infliximab-axxq), a biosimilar to Johnson & Johnson’s Remicade (infliximab).
ViiV submits NDA for drug indicated for multi-drug resistant HIV
ViiV Healthcare has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its first-in-class human immunodeficiency virus (HIV) drug fostemsavir.
FDA approves generics of Novartis multiple sclerosis drug Gilenya
The US Food and Drug Administration (FDA) has approved the first generic versions of Novartis multiple sclerosis drug Gilenya (fingolimod).
AstraZeneca-Merck’s Lynparza approved in China for ovarian cancer
AstraZeneca and Merck (MSD) have received the National Medical Products Administration (NMPA) approval in China for Lynparza (olaparib) to treat advanced germline or somatic BRCA mutated (gBRCAm or sBRCAm) ovarian cancer in adults.
BMS’ Orencia gets breakthrough status in US to prevent GvHD
Bristol-Myers Squibb (BMS) has received breakthrough device designation for its Orencia (abatacept) drug to prevent moderate to severe acute graft-versus-host disease (GvHD).
Roche secures FDA approval for Tecentriq combination in lung cancer
Roche has received the US Food and Drug Administration (FDA) approval to use Tecentriq (atezolizumab) plus Abraxane and carboplatin chemotherapy to treat non-small cell lung cancer (NSCLC) patients.
FDA approves Cumberland’s methotrexate products line
The US Food and Drug Administration (FDA) has approved Cumberland Pharmaceuticals’ methotrexate products to treat adult and paediatric patients with rheumatoid arthritis, as well as adults with psoriasis.
Chidamide gets approval in China for breast cancer indication
Drug development company Chipscreen Biosciences’ oral subtype-selective histone deacetylase (HDAC) inhibitor, Epidaza (Chidamide), has secured approval in China for its second indication.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.